Particularly, people with eczema have a risk of servere disability or death, according to the FDA, due to the live nature of the vaccine. “ACAM2000 carries greater risk of certain serious side effects than Jynneos and cannot be provided to individuals who are immunocompromised or who have heart disease.” However, Nordlund highlighted other problems with the vaccine.

monkeypox outbreak.) ACAM2000 contains live vaccina virus, which is not smallpox, but is closely related. (Dryvax was used to help contain the 2003 U.S. Food and Drug Administration, and replaced Dryvax as the nation’s go-to smallpox vaccine. So what of ACAM2000, the other vaccine that could do the trick? What is ACAM2000?ĪCAM2000 was approved in 2007 by the U.S. Danish company Bavarian Nordic is the only one that can produce it. The vaccine being given to prevent monkeypox, Jynneos, was approved in 2019 for the prevention of smallpox and monkeypox. since 1972, when the disease was considered eradicated here. But smallpox vaccination has not been routine in the U.S.

Monkeypox and smallpox, both of the orthopoxvirus family, are so closely related that both licensed vaccines for smallpox prevention are believed to work for both.

(Photo by Kena Betancur / AFP) (Photo by KENA BETANCUR/AFP via Getty Images) This line in New York City is one of many long lines of people waiting to receive the monkeypox vaccine.

Download backyard baseball 2003